New Treatment Option for Kidney Cancer Patients
The National Comprehensive Cancer Network (NCCN) has updated the NCCN Clinical Practice Guidelines in Oncology™ for Kidney Cancer to reflect March 30 Food and Drug Administration (FDA) approval of everolimas (Afinitor®, Novartis) for advanced renal cell carcinoma.
The NCCN Guidelines Panel for Kidney Cancer has added everolimas as a category 1 option for patients with metastatic renal cell carcinoma following failure of tyrosine kinase therapy.
Clinical trial studies showed the growth or spread of tumors was delayed in patients who were being treated with everolimas and that the treatment improved median progression-free survival to 4.9 months compared to 1.9 months in patients not treated, according to a NCCN press release.
Latest posts by admin aapc (see all)
- US gets the ball rolling on ICD-11 - August 16, 2019
- Message From Your Region 7 Representatives | October 2018 - October 24, 2018
- Message From Your Region 6 Representatives | October 2018 - October 24, 2018